Literature DB >> 35935083

AS-OCT of cyclitic membrane pre and post treatment with rtPA in the anterior chamber.

Emma Marín Payá1, Marina Aguilar González1, Miriam Rahhal Ortuño1, Paula Martínez López Corell1, Jorge Vila Arteaga1, Manuel Díaz Llopis1.   

Abstract

We present the case of a 40-year-old male, who presented to the ophthalmology emergency department with pain and visual loss in his left eye 10 days after an intravitreal injection of a split medication. At the exploration, we found an intense corneal edema in the left eye with endothelial dusting and ciliary hyperemia. LE fundus was impracticable due to anterior chamber opacity. Because of the corneal edema, we performed an anterior segment optical coherence tomography (AS- OCT), visualizing a cyclitic membrane with pupillary block and inflammatory cells in the anterior chamber. There are different treatments to lyse the cyclitic membrane; in this case, we managed the cyclitic membrane with 0,05 ml of intracameral recombinant tissue plasminogen activator (rtPA), a highly potent fibrinolytic protein. We disinfected the eyelids and the conjunctival sac with Povidone Iodine solution, applied topical anesthesia with double anesthetic, and injected 0,05 mL rtPA solution into the anterior chamber using an insulin syringe with a 30-gauge needle. Intracameral rtPA was prepared under sterile conditions using 50 mg vials of rtPA diluted with 50 mL of sterile water to create a 1 mg/ mL solution. Four hours after rtPA treatment, the cyclitic membrane lysed, obtaining pupillary mydriasis. The AS OCT before and after the treatment with intracameral rtPA was of high utility as it allowed the visualization of the cyclitic membrane and its removal.
© The Authors.Romanian Society of Ophthalmology.

Entities:  

Keywords:  AS-OCT; cyclitic membrane; intracameral rtPA; pupillary block

Mesh:

Substances:

Year:  2022        PMID: 35935083      PMCID: PMC9289775          DOI: 10.22336/rjo.2022.37

Source DB:  PubMed          Journal:  Rom J Ophthalmol        ISSN: 2457-4325


  6 in total

1.  Intracameral tissue plasminogen activator use in a large series of eyes with valved glaucoma drainage implants.

Authors:  Alan H Zalta; Charles P Sweeney; Alyson K Zalta; Adam H Kaufman
Journal:  Arch Ophthalmol       Date:  2002-11

2.  Pathogenetic mechanisms in anterior proliferative vitreoretinopathy.

Authors:  P F Lopez; H E Grossniklaus; T M Aaberg; P Sternberg; A Capone; H M Lambert
Journal:  Am J Ophthalmol       Date:  1992-09-15       Impact factor: 5.258

3.  The use of tissue plasminogen activator in silicone oil-filled eyes.

Authors:  P J Kertes; G A Peyman; F Chou; S Meffert; M D Conway
Journal:  Can J Ophthalmol       Date:  1998-02       Impact factor: 1.882

4.  Immunohistochemistry and electron microscopy of cyclitic membrane. Report of a case.

Authors:  C C Chan; L S Fujikawa; M M Rodrigues; G Stevens; R B Nussenblatt
Journal:  Arch Ophthalmol       Date:  1986-07

5.  Intravitreal injection of tissue plasminogen activator as treatment for an occluded pars plana glaucoma tube.

Authors:  Irena Tsui; Suzanna Airiani; Angie Wen; Tarek El-Sawy; Howard F Fine; Peter J G Maris
Journal:  Clin Ophthalmol       Date:  2009-06-02

6.  Dissection of epiciliary tissue to treat chronic hypotony after surgery for retinal detachment with proliferative vitreoretinopathy.

Authors:  M A Zarbin; R G Michels; W R Green
Journal:  Retina       Date:  1991       Impact factor: 4.256

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.